Shares of Rhoen Klinikum AG (ETR:RHK) have received a consensus recommendation of “Hold” from the eleven brokerages that are presently covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a sell recommendation and six have issued a hold recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is €24.10 ($28.02).
RHK has been the subject of a number of recent research reports. Kepler Capital Markets set a €22.00 ($25.58) price objective on Rhoen Klinikum and gave the stock a “sell” rating in a research report on Friday, May 4th. Warburg Research set a €25.20 ($29.30) price objective on Rhoen Klinikum and gave the stock a “neutral” rating in a research report on Friday, May 4th. Berenberg Bank set a €29.15 ($33.90) price objective on Rhoen Klinikum and gave the stock a “neutral” rating in a research report on Monday, May 14th. Cfra set a €25.00 ($29.07) price target on Rhoen Klinikum and gave the company a “sell” rating in a report on Friday, August 3rd. Finally, Credit Suisse Group set a €19.00 ($22.09) price target on Rhoen Klinikum and gave the company a “sell” rating in a report on Monday, August 6th.
Rhoen Klinikum opened at €22.96 ($26.70) on Monday, MarketBeat Ratings reports. Rhoen Klinikum has a 52 week low of €25.08 ($29.16) and a 52 week high of €32.12 ($37.35).
RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services primarily in the areas of cardiovascular, neurological disorders, oncology, pneumology, orthopedic, accident, and surgeries; rehabilitation and nursing services to the elderly; and thoracic, tumors, and psychosomatic, as well as spinal, column, and joints diseases.
See Also: Google Finance
Receive News & Ratings for Rhoen Klinikum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhoen Klinikum and related companies with MarketBeat.com's FREE daily email newsletter.